CTLA4 and neoplasm: In agreement with the transcriptomic changes, RIT induced tumor growth delay and prolonged survival (36 days vs. 23 days in the control group, p < 0.01), and synergized with anti-CTLA4 and anti-PD-1 therapy (median survival >65 days, p < 0.001, vs. RIT alone).